Gardasil delay in older women
Merck's human papillomavirus vaccine Gardasil is unlikely to be approved in women 27 to 45 before 2010. The company received a second "complete response" letter from FDA in response to its sBLA seeking to extend the vaccine's indications to include older women, the firm says Jan. 9. FDA wants additional data from an ongoing clinical trial, FUTURE III, studying Gardasil in that patient population. Merck plans to submit the data to FDA in the fourth quarter when the 48-month trial is finished. Initial filing was based on 24 months of data from the trial. Expanding Gardasil's use to older women has proved challenging because the vaccine is thought to work best in women who have not been exposed to HPV, which is transmitted sexually. Even if Gardasil does receive FDA clearance in older women, the company could face resistance from managed care organizations due to questions about cost effectiveness
You may also be interested in...
Centaur-CytoTools introduces novel topical treatment for diabetic foot ulcers in India, for which they see limited direct competition and hope to change the way the difficult-to-treat diabetes complication is managed. Phase III studies are ongoing in Europe.
The head of the US Food and Drug Administration praised the life-saving work of device center staff in response to the coronavirus pandemic.
Decision on Regeneron’s Ebola virus therapy, which uses a similar monoclonal antibody cocktail approach as the company’s COVID-19 therapy candidate, stands out among the 10 user fee goal dates in the coming month.